A drug utilisation post-authorisation study of new users of aclidinium bromide (monotherapy or in combination) - DUS1/DUS2

Study identifier:D6560R00005

ClinicalTrials.gov identifier:NCT03333018

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Aclidinium Bromide Drug Utilisation Post-Authorisation Safety Studies (DUS): Common Protocol for Aclidinium (DUS1) and Aclidinium/Formoterol Fixed-Dose Combination (DUS2)

Medical condition

Pulmonary Disease, Chronic Obstructive

Phase

N/A

Healthy volunteers

No

Study drug

Aclidinium bromide, Aclidinium bromide/formoterol, Other COPD medication

Sex

All

Actual Enrollment

22155

Study type

Observational

Age

N/A

Date

Study Start Date: 06 Jul 2015
Primary Completion Date: 28 Feb 2017
Study Completion Date: 28 Feb 2017

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2018 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

RTI Health Solutions

Inclusion and exclusion criteria